Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
Authors' conclusion
Semaglutide may improve cardiometabolic risk factors and reduce antihypertensive/lipid-lowering medication use versus placebo in adults with overweight/obesity without diabetes. These potential benefits were not maintained after treatment discontinuation.
Study context
- Population
- Adults with BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 weight-related comorbidity, without diabetesSTEP 1: 1961
- Comparison
- Once-weekly s.c. semaglutide 2.4 mg plus lifestyle intervention vs placebo
- Primary endpoint
- Pre-specified: changes in waist circumference, SBP/DBP, lipids, FPG, fasting serum insulin and antihypertensive/lipid-lowering medication use
Methodological detailsphase III, placebo-controlled, 68-week, STEP 4: 20-week semaglutide run-in and 48-week randomized withdrawal, pre-specified and post-hoc endpoints
- Phase III
- Placebo-controlled
- 68-week
- STEP 4: 20-week semaglutide run-in and 48-week randomized withdrawal
- Pre-specified and post-hoc endpoints
Primary result
As reported in the abstract
STEP 1: waist circumference, SBP, DBP, FPG, fasting serum insulin, lipids and homeostatic model assessment of insulin resistance (HOMA-IR)
- Semaglutide vs Placebo: P ≤ 0.001
Further findings
| Outcome | P value |
|---|---|
| STEP 4: waist circumference, SBP, FPG, fasting serum insulin and lipids after randomized withdrawal · week 20-68 | P < 0.001 [week 20-68] |
| STEP 1: ASCVD riskNon-significant reduction with semaglutide · post-hoc | P > 0.05 |
- STEP 4: waist circumference, SBP, fasting plasma glucose (FPG), fasting serum insulin and lipids after randomized withdrawal: improvements from run-in maintained with continued semaglutide, deteriorated after switch to placebo
STEP 1: SBP, non-HDL cholesterol, LDL-C and FPG within weight-loss categories
- Reductions generally greater with semaglutide than placebo within weight-loss categories
- Post-hoc
Antihypertensive/lipid-lowering medication use (both trials)
- Net reductions with semaglutide vs placebo
Original publication
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. Published 28 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →